Losartan was recalled because of a carcinogenic chemical impurity known as N-nitrosodiethylamine (NDEA), which is a byproduct of the drug manufacturing process.

Torrent Pharmaceuticals announced an initial recall on December 20 after finding NDEA in 2 lots of the active ingredient manufactured by Hetero Labs Limited.

On January 3, Torrent announced an expanded recall covering 12 lots of the dug.

The recall involves Lorsartan Potassium Tablets, USP, in 100-mg, 50-mg and 25-mg strengths. They were sold and in bottles of 30, 90, and 1,000 count, with expiration dates ranging from 04/2019 through 05/2021.

Losartan is a generic version of the blood pressure medication Cozaar®, and because it is meant to be taken every day, a carcinogenic impurity could potentially raise a user’s risk of cancer.

NDEA is a byproduct of industrial processes that is listed as a probable human carcinogen by the International Agency for Research on Cancer (IARC). Problems with NDEA impurities have also been linked to the blood pressure drugs irbesartan and valsartan.

Source: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP

Posted by Daily Hornet

We aim to provide progressive news that covers politics and corporate wrongdoing. We have no corporate interests to serve. No hidden agenda. We’re here to bring you the news you need to know with a grassroots twist.

2 Comments

  1. losartan is the generic for hyzaar , so what about this one

    Reply

    1. Maybe… FDA said the voluntarily recall applies to 100mg/25mg tablets of Hyzaar containing losartan, with the lot number JB8912. Sandoz distributed the affected lot nationally on or after Oct. 8, 2018.

      Reply

Leave a reply

Your email address will not be published.